CALYX
CALYX is a privately held biotechnology research company with over 25 years of experience in clinical development, specializing in eClinical solutions and services. With a global presence and a commitment to environmental practices, CALYX has supported over 60,000 clinical trials and contributed to the approval of more than 650 medical treatments.
Services
Calyx offers a comprehensive range of services designed to support clinical trial sponsors and clinical research organizations (CROs). These services include Medical Imaging, Interactive Response Technology (IRT), Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Regulatory Information Management (RIM). The company specializes in eClinical solutions that enhance the efficiency and effectiveness of clinical trials. Additionally, Calyx provides scientific and technical consulting services, ensuring that clients receive expert guidance throughout the clinical development process.
Global Presence
Calyx maintains a global presence with offices strategically located in Europe, America, and Asia. The company has headquarters in Nottingham, UK, and Burlington, Massachusetts, USA. It also has offices in major cities including Shanghai and Beijing in China, Tokyo in Japan, and Hyderabad in India, as well as Berlin, Germany. This extensive network enables Calyx to support clinical trials across various regions and time zones, providing 24/7 global customer support.
Experience in Clinical Development
With over 25 years of experience in clinical development, Calyx has played a significant role in bringing new medical treatments to market more efficiently. The company has supported over 60,000 clinical trials and has been involved in the approval of more than 650 drugs, including breakthrough therapies. Calyx's expertise extends to oncology, CNS, and musculoskeletal imaging services, as well as tumor response criteria and imaging modalities.
Commitment to Sustainability
Calyx demonstrates a strong commitment to environmental, social, and governance (ESG) practices. The company aims to reduce direct greenhouse gas emissions by 35% by 2027 and indirect emissions by 30% by 2032. Calyx has implemented a supplier diversity program with a goal of achieving 15% spend on small and diverse businesses. Additionally, the company is committed to using clean energy at its headquarters in Nottingham, UK, reflecting its dedication to sustainable practices.
Founders and Company Structure
Calyx is classified as a privately held company and operates as a very large enterprise with a team size of 1,513 employees. The company describes itself as 'Reliably Solving the Complex,' indicating its focus on addressing intricate challenges within the clinical development landscape. While specific founder information is not provided, the company's long-standing presence in the biotechnology research industry highlights its established role in the field.